Press Releases Active Biotech AB

Equities

ACTI

SE0001137985

Delayed Nasdaq Stockholm Other stock markets 03:31:16 2024-04-29 am EDT			5-day change	1st Jan Change
0.55 ^SEK	-3.00%		+1.79%	+24.64%

Apr. 03	Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	CI
Feb. 08	Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annual Report 2023 Active Biotech AB (publ)	Apr. 22	AQ
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops	Apr. 03	AQ
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024	Feb. 09	AQ
Active Biotech Year End Report 2023	Feb. 08	AQ
Number of shares and votes in Active Biotech	Dec. 29	AQ
Active Biotech provides update on the scheduled clinical program for 2024	Dec. 22	AQ
Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website	Dec. 14	AQ
Active Biotech announces outcome of the Company’s rights issue	Dec. 06	AQ
Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod	Dec. 05	AQ
Active Biotech's nomination committee appointed	Dec. 01	AQ
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis	Dec. 01	AQ
Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue	Nov. 29	AQ
Active Biotech publishes prospectus	Nov. 13	AQ
Active Biotech Q3 2023 - Rights Issue Paves the Way for Phase II in Myelofibrosis	Nov. 10	AQ
Active Biotech announces a rights issue of approximately SEK 51 million	Nov. 09	AQ
Active Biotech Interim Report Q3 2023	Nov. 09	AQ
Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023	Nov. 02	AQ
Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech's website	23-09-13	AQ
Tasquinimod successfully completes dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort	23-09-11	AQ
Active Biotech Q2 2023 - New Focus on Myelofibrosis	23-08-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Active Biotech AB

Equities

ACTI

SE0001137985

Press Releases

Filters